Journal of Affective Disorders
Volume 75, Issue 1 , Pages 1-10 , June 2003

Cyclothymic OCD: a distinct form?

  • E.G. Hantouche

      Affiliations

    • Mood Center, Department of Psychiatry, Pitié-Salpêtrière Hospital, 47 Bd de l’Hôpital, 75013 Paris, France
    • Corresponding Author InformationCorresponding author.
    • ,
  • J. Angst

      Affiliations

    • Zurich University Psychiatric Hospital, Zurich, Switzerland
    • ,
  • C. Demonfaucon

      Affiliations

    • AFTOC, Chateaufort, France
    • ,
  • G. Perugi

      Affiliations

    • Psychiatric Institute of Pisa, Pisa, Italy
    • ,
  • S. Lancrenon

      Affiliations

    • Syliastat, Antony, France
    • ,
  • H.S. Akiskal

      Affiliations

    • International Mood Center, VA Hospital and University of California, San Diego, CA, USA

Received 30 January 2002 ,Accepted 2 April 2002.

References 

  1. Akiskal HS, Pinto O. The evolving bipolar spectrum: prototypes I, II, III and IV. PCNA. 1999;22:517–534
  2. Akiskal HS, Hantouche EG, Bourgeois ML, Azorin JM, Sechter D, Allilaire JF, et al. Toward a refined phenomenology of DSM-IV mania: Combining clinician-assessment and self-report in the French EPIMAN study. J. Affect. Disord. 2001;67:89–96
  3. Akiskal HS, Hantouche EG, Lancrenon S. BP-II with and without cyclothymic temperament: “dark” and “sunny” expressions. J. Affect. Disord. 2003;73:49–57
  4. Allilaire JF, Hantouche EG, Sechter D, Bourgeois ML, Azorin JM, Lancrenon S, et al. Fréquence et aspects cliniques du trouble BP-II dans une étude multicentrique française: EPIDEP. Encephale. 2001;27:149–158
  5. Altman E. Rating scales for mania: is self-rating reliable?. J. Affect. Disord. 1998;50:283–286
  6. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord. 1998;50:143–151
  7. Angst, J., Hantouche, E.G., 2002. The epidemiology of minor bipolar disorder and hypomania: new territory. In: Vieta, E. (Ed.), Hypomania, Aula Médica Bibliotecas, Madrid, pp. 13–31.
  8. Ballet G. La mélancolie intermittente. Presse Med. 1902;39:459–462
  9. Berk M, Koopowitz LE, Szabo CP. Antidepressant-induced mania in OCD. Eur. Neuropsychopharmacol. 1996;6:9–11
  10. Chen YW, Dilsaver SC. Comorbidity for OCD in bipolar and unipolar disorders. Psychiatry Res. 1995;59:57–64
  11. De HL, Beuk N, Hoogenboom B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders. J. Clin. Psychiatry. 2002;63:104–107
  12. Demonfaucon C, Hantouche EG. Approche dimensionnelle des rapports entre TOC et bipolarité: interactions entre émotivité, impulsivité, lenteur et place centrale de la symétrie. Synapse. 2001;180:31–40
  13. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J. Child. Adolesc. Psychopharmacol. 1999;9:115–123
  14. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can. J. Psychiatry. 2001;46:356–358
  15. Hantouche EG, Akiskal HS, Lancrenon S Allilaire JF, Sechter D, Azorin JM, Bourgeois M, et al. Systematic clinical methodology for validating BP-II disorder: data in mid-stream from a French national study (EPIDEP). J. Affect. Disord. 1998;50:163–175
  16. Hantouche EG, Akiskal HS, Bourgeois ML, Azorin JM, Sechter D, Allilaire JF, et al. The feasibility of self-assessment of dysphoric mania in the French national EPIMAN study. J. Affect. Disord. 2001;67:97–103
  17. Hantouche EG, Akiskal HS, Demonfaucon C, Barrot I, Kochman F, Millet B, et al. Bipolarité cachée dans le trouble obsessionnel compulsif: enquête collaboratı̂ve avec l’AFTOC. Ann. Med. Psychol. 2002;160:34–41
  18. Hantouche EG, Kochman F, Demonfaucon C, Barrot I, Millet B, Lancrenon S, et al. TOC bipolaire: confirmation des résultats de l’enquête «ABC-TOC» dans deux populations de patients adhérents versus non adhérents à une association. Encephale. 2002;28:21–28
  19. Hantouche EG, Angst J, Akiskal HS. Factor structure of hypomania: Interrelationships with cyclothymia and soft bipolar spectrum. J. Affect. Disord. 2003;73:39–47
  20. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J. Clin. Psychiatry. 1995;56:423–429
  21. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS. J. Psychiatry Neurosci. 2001;26:55–59
  22. Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry. 2000;61:514–517
  23. Lester D, Abdel-Khalek AM. Manic-depression, suicidality, and obsessive-compulsive tendencies. Psychol. Rep. 1999;85:1100
  24. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry. 2000;57:794–801
  25. Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int. Clin. Psychopharmacol. 2002;17:37–40
  26. Perugi G, Akiskal HS, Pfanner C, Presta S, Gemignani A, Milanfranchi A, et al. The clinical impact of bipolar and unipolar affective comorbidity on obsessive-compulsive disorder. J. Affect. Disord. 1997;46:15–23
  27. Perugi G, Akiskal HS, Gemignani A, Pfanner C, Presta S, Milanfranchi A, et al. Episodic course in obsessive-compulsive disorder. Eur. Arch. Psychiatr. Clin. Neurosci. 1998;248:240–244
  28. Perugi G, Akiskal HS, Ramacciotti S, Nassini S, Toni C, Milanfranchi A, et al. Depressive comorbidity of panic, social phobia, and OCD re-examined: is there a bipolar II connection?. J. Psychiatry Res. 1999;33:53–61
  29. Perugi, G., Toni, C., Frare, F., Travierso, C., Hantouche, E., Akiskal, H.S., 2003. Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcomes. J. Clin. Psychiatry, in press.
  30. Pfanner C, Marazziti D, Dell’Osso L, Presta S, Gemignani A, Milanfranchi A, et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int. Clin. Psychopharmacol. 2000;15:297–301
  31. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol. Bull. 1996;32:677–682
  32. Saxena S, Wang D, Bystritsky A, Baxter LR. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J. Clin. Psychiatry. 1996;57:303–306
  33. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry. 1997;58:119–122
  34. Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J. Clin. Psychiatry. 1999;60:524–527

PII: S0165-0327(02)00461-5

doi: 10.1016/S0165-0327(02)00461-5

Journal of Affective Disorders
Volume 75, Issue 1 , Pages 1-10 , June 2003

Article Tools